NC
CRDF icon

NewSquare Capital’s Cardiff Oncology CRDF Stock Holding History

NewSquare Capital’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-125
Closed -$184 – 654
2023
Q2 		$184 Hold
125
– – ﹤0.01% 764
2023
Q1 		$206 Hold
125
– – ﹤0.01% 790
2022
Q4 		$175 Buy
+125
New +$179 ﹤0.01% 742

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NewSquare Capital's CRDF Position: Q3 2023 in Review

NewSquare Capital sold out of Cardiff Oncology (CRDF) in Q3 2023, closing a stake of 125 shares — an estimated $184 sold.

NewSquare Capital first reported a position in CRDF in Q4 2022 and held it in 3 quarters. The position peaked at $206 in Q1 2023. 55 funds tracked by Wall St. Rank hold CRDF as of Q3 2023.

  • NewSquare Capital reported no remaining Cardiff Oncology position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 125 Cardiff Oncology shares in Q3 2023, an estimated $184.
  • NewSquare Capital first reported a position in Cardiff Oncology in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Cardiff Oncology position peaked at $206 in Q1 2023.
  • 55 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.